Best Interventions for Gout Flares

Save

A recent metanalysis assessed the comparative efficacy of current first-line pharmacologic antiinflammatory interventions for gout flares and surmised that canakinumab and intravenous or intramuscular corticosteroids are superior to  nonsteroidal antiinflammatory drugs [NSAIDs].

RheumNow Podcast – Heart, Lung & Liver (5.28.2021)

Save

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Efficacy of 6 Weeks Antibiotics with Prosthetic Joint Infections

Save

The NEJM has published the results of a French multicenter study showing that prosthetic joint infections can be successfully managed with 6 weeks of antibiotic therapy; this was noninferior and had better outcomes compared to 12 weeks of antibiotic therapy.

EULAR Guidelines on Intraarticular Therapy

Save

EULAR has published evidence-based recommendations on the use of intra-articular therapies (IAT) based on the literature review and recommendations of a multidisciplinary international task force. These IAT recommendations apply to adult patients with peripheral arthropathies.

Tocilizumab Risk of Diverticulitis and GI Perforation

Save

A French registry analysis compared the risk of diverticulitis and gastrointestinal perforation (GIP) in rheumatoid arthritis (RA) patients treated with biologics and found a greater risk of both in patients receiving tocilizumab (TCZ) compared with those on rituximab (RTX) or abatacept (ABA

RheumNow Podcast – BandAids for Rheumatologists (5.14.2021)

Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com - a website for rheumatologists, by rheumatologists.

We love Rheumatology!

Risk Factors for Rheumatoid Arthritis-associated Interstitial Lung Disease

Save

Sparks and colleagues have published a matched cohort analysis demonstrating risk factors that may augment the risk of rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), especially the combination of obesity, high CRP, high MD-HAQ and >30 pack-year smoking h

FDA Advisors Split on Avacopan for Vasculitis

Save

Members of an FDA advisory panel were sharply divided as to whether avacopan, an oral small molecule inhibitor of the C5a receptor, was sufficiently safe and effective for treating antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Avacopan for ANCA Vasculitis Goes in Front of the FDA

Save

An FDA advisory panel will consider whether to recommend approval of an oral C5a inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, with agency staff raising questions over the "clinical meaningfulness" of key study data.

RheumNow Podcast – Falling or Falling in Love?

Save

Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.

Childhood Lupus May Hamper Adult Careers

Save

Long-term outcomes of kids with childhood-onset systemic lupus erythematosus (cSLE) are uncommon, but this cSLE cohort analysis suggests that SLE significantly impacts their future education, vocation, and employment as they reach adulthood.

RheumNow Podcast – Uppers and Downers

Save

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

RheumNow Podcast – Coconspirators: RA and Lung Disease

Save

Dr. Jack Cush reviews and discusses more than a dozen news and journal articles from the past week on RheumNow.com.

DMARD Dropouts During COVID-19

Save

A full year from the onset of the SARS-COV-2 pandemic, rheumatologists are still seeing the consequences of COVID, with many patients avoiding usual care, follow-up visits, routine lab testing and with many self-stopping their antirheumatic meds, because it seemed like the right thing to do.

RheumNow Podcast – Mistakes with Steroids

Save

Dr Jack Cush gives his spin on this week's RheumNews and Rheum Research from RheumNow.com.

Overview of New VEXAS Syndrome

Save

Medscape offers up an informative overview of the newly described syndrome called VEXAS discovered by researchers at the National Institutes of Health.